KR100785182B1 - 수면 장애를 위한 가바펜틴 유사체 - Google Patents

수면 장애를 위한 가바펜틴 유사체 Download PDF

Info

Publication number
KR100785182B1
KR100785182B1 KR1020027017609A KR20027017609A KR100785182B1 KR 100785182 B1 KR100785182 B1 KR 100785182B1 KR 1020027017609 A KR1020027017609 A KR 1020027017609A KR 20027017609 A KR20027017609 A KR 20027017609A KR 100785182 B1 KR100785182 B1 KR 100785182B1
Authority
KR
South Korea
Prior art keywords
aminomethyl
acetic acid
cyclopentyl
methyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027017609A
Other languages
English (en)
Korean (ko)
Other versions
KR20030019455A (ko
Inventor
저스틴 스티븐 브라이언스
레오나르드 데오도르 멜트저
Original Assignee
워너-램버트 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워너-램버트 캄파니 엘엘씨 filed Critical 워너-램버트 캄파니 엘엘씨
Publication of KR20030019455A publication Critical patent/KR20030019455A/ko
Application granted granted Critical
Publication of KR100785182B1 publication Critical patent/KR100785182B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020027017609A 2000-06-26 2001-05-18 수면 장애를 위한 가바펜틴 유사체 Expired - Fee Related KR100785182B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21417100P 2000-06-26 2000-06-26
US60/214,171 2000-06-26
PCT/US2001/016343 WO2002000209A2 (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders

Publications (2)

Publication Number Publication Date
KR20030019455A KR20030019455A (ko) 2003-03-06
KR100785182B1 true KR100785182B1 (ko) 2007-12-11

Family

ID=22798045

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017609A Expired - Fee Related KR100785182B1 (ko) 2000-06-26 2001-05-18 수면 장애를 위한 가바펜틴 유사체

Country Status (23)

Country Link
US (1) US7141606B2 (cg-RX-API-DMAC7.html)
EP (1) EP1296671B1 (cg-RX-API-DMAC7.html)
JP (1) JP3909842B2 (cg-RX-API-DMAC7.html)
KR (1) KR100785182B1 (cg-RX-API-DMAC7.html)
CN (1) CN1279900C (cg-RX-API-DMAC7.html)
AT (1) ATE390133T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001264736B2 (cg-RX-API-DMAC7.html)
BR (1) BR0111913A (cg-RX-API-DMAC7.html)
CA (1) CA2414008C (cg-RX-API-DMAC7.html)
CZ (1) CZ20024110A3 (cg-RX-API-DMAC7.html)
DE (1) DE60133389T2 (cg-RX-API-DMAC7.html)
DK (1) DK1296671T3 (cg-RX-API-DMAC7.html)
ES (1) ES2300332T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0300833A3 (cg-RX-API-DMAC7.html)
IL (2) IL152770A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02010668A (cg-RX-API-DMAC7.html)
NZ (1) NZ522480A (cg-RX-API-DMAC7.html)
PL (1) PL359872A1 (cg-RX-API-DMAC7.html)
PT (1) PT1296671E (cg-RX-API-DMAC7.html)
SK (1) SK17922002A3 (cg-RX-API-DMAC7.html)
TW (1) TWI298020B (cg-RX-API-DMAC7.html)
WO (1) WO2002000209A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200209418B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444053C (en) 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AU2003283718A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
EP1622603A4 (en) * 2003-03-25 2010-03-24 Kiel Lab Inc GABAPENTINIC PHENOLIC ACID SALTS IN SOLID DOSAGE FORMS AND METHODS OF USE
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
CA2538802C (en) 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
JP4613031B2 (ja) * 2004-05-06 2011-01-12 エスエス製薬株式会社 催眠剤組成物
JP2005325070A (ja) * 2004-05-14 2005-11-24 Ss Pharmaceut Co Ltd 睡眠改善剤
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
AU2006262502A1 (en) 2005-06-23 2007-01-04 Emory Univerisity Imaging agents
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CA2640402C (en) * 2006-03-06 2012-01-03 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
SG10201912843YA (en) * 2016-05-26 2020-02-27 Amino Up Chemical Co Ltd Sleep improving agent
JP7441181B2 (ja) 2018-05-14 2024-02-29 エックスジーン ファーマシューティカル インク. ナプロキセンとプレガバリンの1-(アシルオキシ)-アルキルカルバメート薬品複合体の結晶形態
CN117776950B (zh) * 2022-09-20 2025-12-23 中科中山药物创新研究院 一种γ-氨基丁酸衍生物、药物组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002546A2 (en) * 1998-07-09 2000-01-20 Warner-Lambert Company Use of caba-analogues for treating insomnia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
EA001214B1 (ru) * 1996-03-14 2000-12-25 Варнер-Ламберт Компани Новые мостиковые циклические аминокислоты как фармацевтически применимые вещества
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
ATE323067T1 (de) * 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
JP2003525207A (ja) * 1999-06-02 2003-08-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 薬剤として有用なアミノ複素環
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
BR0016201A (pt) * 1999-12-08 2002-08-13 Warner Lambert Co Método para a sìntese estereosseletiva de aminoácidos cìclicos
GB9930083D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002546A2 (en) * 1998-07-09 2000-01-20 Warner-Lambert Company Use of caba-analogues for treating insomnia

Also Published As

Publication number Publication date
HUP0300833A3 (en) 2009-08-28
SK17922002A3 (sk) 2003-11-04
TWI298020B (en) 2008-06-21
IL152770A0 (en) 2003-06-24
CA2414008A1 (en) 2002-01-03
DK1296671T3 (da) 2008-06-16
CN1279900C (zh) 2006-10-18
DE60133389D1 (de) 2008-05-08
KR20030019455A (ko) 2003-03-06
CA2414008C (en) 2011-04-26
DE60133389T2 (de) 2008-06-26
ES2300332T3 (es) 2008-06-16
JP3909842B2 (ja) 2007-04-25
CZ20024110A3 (cs) 2003-10-15
NZ522480A (en) 2005-06-24
US7141606B2 (en) 2006-11-28
PL359872A1 (en) 2004-09-06
CN1436075A (zh) 2003-08-13
AU6473601A (en) 2002-01-08
ZA200209418B (en) 2005-03-10
PT1296671E (pt) 2008-05-09
HUP0300833A2 (hu) 2003-08-28
EP1296671A2 (en) 2003-04-02
JP2004501189A (ja) 2004-01-15
WO2002000209A3 (en) 2003-01-16
HK1056681A1 (en) 2004-02-27
US20030212133A1 (en) 2003-11-13
IL152770A (en) 2009-12-24
AU2001264736B2 (en) 2006-04-27
EP1296671B1 (en) 2008-03-26
ATE390133T1 (de) 2008-04-15
MXPA02010668A (es) 2003-03-10
WO2002000209A2 (en) 2002-01-03
BR0111913A (pt) 2004-01-06

Similar Documents

Publication Publication Date Title
JP3909842B2 (ja) 睡眠障害のためのガバペンチン類似物
AU2001264736A1 (en) Gabapentin analogues for sleep disorders
US4877620A (en) Ibuprofen-containing medicament
ES2273764T3 (es) Nuevos tratamientos que utilizan derivados de fenetilamina.
US20080167366A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
PT867179E (pt) Composicao de esteres de l-dopa
RU2005104418A (ru) Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин
HUP0303983A2 (hu) Peptidvegyületek új alkalmazása az allodynia vagy más krónikus vagy fantom típusú fájdalom kezelésére
WO1993006826A1 (en) Composition comprising s-oxiracetame for use as nootropic
KR20010071778A (ko) 불면증의 치료를 위한 gaba 유사체의 용도
AU2002340971A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
US6458840B2 (en) Use of valproic acid analog for the treatment and prevention of migraine and affective illness
US3557292A (en) Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
CN102670597B (zh) 5-(4-羟基-3-甲氧基苯亚甲基)罗丹宁在制备治疗帕金森氏病药物中的用途
US5948806A (en) Treatment of Parkinson's disease with (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-Imidazoline (dexefaroxan or (+) efaroxan)
EP0707477B1 (fr) Utilisation de l'efaroxan et de ses derives pour la fabrication de medicaments destines au traitement des maladies neurodegeneratives
CA2640402C (en) Alpha-2-delta ligands for non-restorative sleep
HU202111B (en) Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component
HK1129040A (en) Alpha-2-delta ligands for non-restorative sleep

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080414

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007851820000

Gazette reference publication date: 20071211

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20111129

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20121206

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20121206

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000